Zacks Research Has Bullish Forecast for A Q2 Earnings

Agilent Technologies, Inc. (NYSE:A - Free Report) - Zacks Research upped their Q2 2026 EPS estimates for shares of Agilent Technologies in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $1.47 for the quarter, up from their previous estimate of $1.46. The consensus estimate for Agilent Technologies' current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies' Q4 2026 earnings at $1.70 EPS and FY2027 earnings at $6.67 EPS.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm's revenue was up .8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.38 EPS.

A number of other equities analysts also recently issued reports on A. Evercore ISI raised their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an "in-line" rating in a research report on Tuesday, October 1st. UBS Group boosted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a "neutral" rating in a report on Thursday, August 22nd. JPMorgan Chase & Co. decreased their price target on Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a report on Tuesday, November 26th. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Citigroup raised their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $143.62.

Agilent Technologies Trading Down 1.0 %

Agilent Technologies stock traded down $1.33 during trading hours on Monday, hitting $137.67. The stock had a trading volume of 1,578,434 shares, compared to its average volume of 1,721,431. The business's 50 day simple moving average is $136.75 and its 200-day simple moving average is $136.37. Agilent Technologies has a one year low of $124.16 and a one year high of $155.35. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The stock has a market cap of $39.56 billion, a price-to-earnings ratio of 31.45, a P/E/G ratio of 4.48 and a beta of 1.07.

Agilent Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be given a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.72%. This is an increase from Agilent Technologies's previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. Agilent Technologies's dividend payout ratio (DPR) is presently 22.40%.

Insider Buying and Selling

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares of the company's stock, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Crewe Advisors LLC lifted its stake in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock valued at $25,000 after buying an additional 101 shares in the last quarter. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies during the third quarter worth $28,000. Ridgewood Investments LLC bought a new position in shares of Agilent Technologies in the second quarter worth $29,000. Ashton Thomas Securities LLC purchased a new position in shares of Agilent Technologies in the third quarter valued at $31,000. Finally, Fortitude Family Office LLC raised its stake in shares of Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock valued at $35,000 after purchasing an additional 95 shares during the period. Hedge funds and other institutional investors own 87.42% of the company's stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.